FARKA, Zdeněk, Julian BRANDMEIER, Matthias Jürgen MICKERT, Matěj PASTUCHA, Karel LACINA, Petr SKLÁDAL, Tero SOUKKA and Hans-Heiner GORRIS. Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market. Advanced Materials. Weinheim: Wiley-VCH, 2024, vol. 36, No 3, p. 1-23. ISSN 0935-9648. Available from: https://dx.doi.org/10.1002/adma.202307653.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market
Authors FARKA, Zdeněk (203 Czech Republic, belonging to the institution), Julian BRANDMEIER (276 Germany, belonging to the institution), Matthias Jürgen MICKERT (276 Germany), Matěj PASTUCHA (203 Czech Republic, belonging to the institution), Karel LACINA (203 Czech Republic, belonging to the institution), Petr SKLÁDAL (203 Czech Republic, belonging to the institution), Tero SOUKKA (246 Finland) and Hans-Heiner GORRIS (276 Germany, guarantor, belonging to the institution).
Edition Advanced Materials, Weinheim, Wiley-VCH, 2024, 0935-9648.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10406 Analytical chemistry
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 29.400 in 2022
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1002/adma.202307653
UT WoS 001118500300001
Keywords in English bioaffinity assay; immunoassay; nanoparticle; nanomaterial; commercialization
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 4/3/2024 09:42.
Abstract
Advances in the development of new biorecognition elements, nanoparticle-based labels as well as instrumentation have inspired the design of new bioaffinity assays. This review critically discusses the potential of nanoparticles to replace current enzymatic or molecular labels in immunoassays and other bioaffinity assays. Successful implementations of nanoparticles in commercial assays and the need for rapid tests incorporating nanoparticles in different roles such as capture support, signal generation elements, and signal amplification systems are highlighted. The limited number of nanoparticles applied in current commercial assays can be explained by challenges associated with the analysis of real samples (e.g., blood, urine, or nasal swabs) that are difficult to resolve, particularly if the same performance can be achieved more easily by conventional labels. Lateral flow assays that are based on the visual detection of the red-colored line formed by colloidal gold are a notable exception, exemplified by SARS-CoV-2 rapid antigen tests that have moved from initial laboratory testing to widespread market adaption in less than two years.
Links
GF23-06199K, research and development projectName: Nové anti-Stokesové lanthanoidové nanočástice a vícebarevný FRET mechanismy pro jednomolekulové sekvenování DNA
Investor: Czech Science Foundation, Novel anti-Stokes upconverting nanoparticles and multicolor FRET mechanisms for single-molecule DNA sequencing, Lead Agency
PrintDisplayed: 29/5/2024 17:46